semaglutide essence trial for MASH in #ESSENCE #Semaglutide hits both primary endpoints in NASH trial 📍62.9% resolved steatohepatitis (vs 34.3% placebo) 📍36.8% showed fibrosis improvement (vs 22.4% placebo) 📍Combined response: 32.7% vs 16.1% S5-26.1 - Looking Back at

Not everyone on Semaglutide suffers from Ozempic face, but there are other concerns

Can Retatrutide Cause Nausea

A.HabenerJ

Integration: Match creatine use with resistance training, adequate protein (0.8 to 1.2 grams per kilogram per day or more during hypocaloric plans), and regular clinical follow-up

Future investigations should include diabetic populations with PD to properly assess the efficacy profile of GLP-1 receptor agonists and determine whether the observed improvement in the MDS-UPDRS Part III score (MD = 2.88

It is also worth speaking with a healthcare professional if you are struggling with weight management despite consistent training and nutrition efforts, as there may be underlying hormonal or metabolic issues that need addressing